5 Ultra-Popular Stocks to Avoid Like the Plague in July

The motley fool2021-07-06

For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020. While ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

holdnotfold
2021-07-06
holdnotfold
Orh ok
Sephy
2021-07-06
Sephy
Newbie analysts gg. Load up coinbase now u will be HUGELY rewarded by August earnings report at least a 20% profit, projected 20-40%.
- 6c65da76:
  Seems Like you are a bagholder, Its a pump and dump, I got burnt in this stock too.
- 6c65da76:
  Look how ERs didnt even affect the stock price hugely
- Sephy:
  its correlated to bitcoin and ethereum prices
- Sephy回复Sephy:
  The previous ER their price went up to 300, the upcoming ER i am confident it will go to 32x at least depending on btc n eth price
- Sephy:
  Btw im not a bagholder im a professional trader, good luck @@
StanleyO
2021-07-06
StanleyO
Good Read
Patek1975
2021-07-06
Patek1975
Lousy article as usual from fools , how much yougetting paid for this article
Patek1975
2021-07-06
Patek1975
Apes hold [Smile]
Xuehao
2021-07-06
Xuehao
Too the moonn, like n share tq

发表看法

181

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1164348327?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-07-06 09:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164348327","market":"us","top_or_hot":-1,"title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July","media":"The motley fool","content":"<div>\n<p>For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 09:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/><strong>The motley fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GME","symbol_name":"游戏驿站","start_time":0,"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","article_id":"1164348327","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","pubTimestamp":1625535165,"sourceInfo":null,"weMediaInfo":null,"summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"GME":"游戏驿站","SAVA":"Cassava Sciences Inc","AMC":"AMC院线","COIN":"Coinbase Global, Inc.","INO":"伊诺维奥制药"},"translate_title":"5只超人气股要避开7月的瘟疫","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMC":0.9,"COIN":0.9,"GME":0.9,"INO":0.9,"SAVA":0.9},"content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","kind":null,"is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":157056825,"gmtCreate":1625556968867,"gmtModify":1631891845827,"author":{"id":"3585783282279083","authorId":"3585783282279083","name":"holdnotfold","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3585783282279083","authorIdStr":"3585783282279083"},"htmlText":"Orh ok","listText":"Orh ok","text":"Orh ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/157056825","repostId":1164348327,"repostType":2,"repost":{"id":"1164348327","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"<p>For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmark<b>S&amp;P 500</b>has gained more than 90% since hitting its bear-market bottom on March 23, 2020.</p>\n<p>While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.</p>\n<p>Coinbase Global</p>\n<p>First up is cryptocurrency exchange and ecosystem<b>Coinbase Global</b>(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes of<b>Bitcoin</b>&nbsp;and<b>Ethereum</b>. The problem is there are a trio of catalysts working against the Coinbase brokerage model.</p>\n<p>To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.</p>\n<p>Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.</p>\n<p>And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.</p>\n<p>Cassava Sciences</p>\n<p>Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stock<b>Cassava Sciences</b>(NASDAQ:SAVA).</p>\n<p>Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.</p>\n<p>I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception of<b>Biogen</b>'s Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.</p>\n<p>Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.</p>\n<p>GameStop</p>\n<p>If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailer<b>GameStop</b>(NYSE:GME).</p>\n<p>On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.</p>\n<p>However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.</p>\n<p>GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.</p>\n<p>Inovio Pharmaceuticals</p>\n<p>Biotech stocks can offer ample opportunity, or in<b>Inovio Pharmaceuticals</b>'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.</p>\n<p>Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.</p>\n<p>For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.</p>\n<p>If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.</p>\n<p>AMC Entertainment</p>\n<p>Finally, I can't forgetongoing pump-and-dump scheme<b>AMC Entertainment</b>(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.</p>\n<p>AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.</p>\n<p>AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.</p>\n<p>I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 09:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/><strong>The motley fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","AMC":"AMC院线","GME":"游戏驿站","COIN":"Coinbase Global, Inc.","INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":157068326,"gmtCreate":1625554713865,"gmtModify":1631884614003,"author":{"id":"3579782126622830","authorId":"3579782126622830","name":"Sephy","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579782126622830","authorIdStr":"3579782126622830"},"htmlText":"Newbie&nbsp;analysts gg. Load up coinbase now u will be HUGELY rewarded by August earnings report at least a 20% profit, projected 20-40%.&nbsp;&nbsp;","listText":"Newbie&nbsp;analysts gg. Load up coinbase now u will be HUGELY rewarded by August earnings report at least a 20% profit, projected 20-40%.&nbsp;&nbsp;","text":"Newbie analysts gg. Load up coinbase now u will be HUGELY rewarded by August earnings report at least a 20% profit, projected 20-40%.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/157068326","repostId":1164348327,"repostType":2,"repost":{"id":"1164348327","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"<p>For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmark<b>S&amp;P 500</b>has gained more than 90% since hitting its bear-market bottom on March 23, 2020.</p>\n<p>While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.</p>\n<p>Coinbase Global</p>\n<p>First up is cryptocurrency exchange and ecosystem<b>Coinbase Global</b>(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes of<b>Bitcoin</b>&nbsp;and<b>Ethereum</b>. The problem is there are a trio of catalysts working against the Coinbase brokerage model.</p>\n<p>To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.</p>\n<p>Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.</p>\n<p>And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.</p>\n<p>Cassava Sciences</p>\n<p>Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stock<b>Cassava Sciences</b>(NASDAQ:SAVA).</p>\n<p>Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.</p>\n<p>I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception of<b>Biogen</b>'s Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.</p>\n<p>Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.</p>\n<p>GameStop</p>\n<p>If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailer<b>GameStop</b>(NYSE:GME).</p>\n<p>On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.</p>\n<p>However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.</p>\n<p>GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.</p>\n<p>Inovio Pharmaceuticals</p>\n<p>Biotech stocks can offer ample opportunity, or in<b>Inovio Pharmaceuticals</b>'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.</p>\n<p>Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.</p>\n<p>For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.</p>\n<p>If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.</p>\n<p>AMC Entertainment</p>\n<p>Finally, I can't forgetongoing pump-and-dump scheme<b>AMC Entertainment</b>(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.</p>\n<p>AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.</p>\n<p>AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.</p>\n<p>I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 09:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/><strong>The motley fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","AMC":"AMC院线","GME":"游戏驿站","COIN":"Coinbase Global, Inc.","INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5136859,"gmtCreate":1625566914781,"gmtModify":1635236002796,"authorId":3579334079758210,"author":{"id":3579334079758210,"idStr":"3579334079758210","authorId":3579334079758210,"name":"6c65da76","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":157068326,"type":1,"supId":0,"prevId":0,"content":"Seems Like you are a bagholder, Its a pump and dump, I got burnt in this stock too.","text":"Seems Like you are a bagholder, Its a pump and dump, I got burnt in this stock too.","html":"Seems Like you are a bagholder, Its a pump and dump, I got burnt in this stock too."},{"id":5136865,"gmtCreate":1625566956617,"gmtModify":1635236002290,"authorId":3579334079758210,"author":{"id":3579334079758210,"idStr":"3579334079758210","authorId":3579334079758210,"name":"6c65da76","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":157068326,"type":1,"supId":0,"prevId":0,"content":"Look how ERs didnt even affect the stock price hugely","text":"Look how ERs didnt even affect the stock price hugely","html":"Look how ERs didnt even affect the stock price hugely"},{"id":5138635,"gmtCreate":1625578387374,"gmtModify":1635235883358,"authorId":3579782126622830,"author":{"id":3579782126622830,"idStr":"3579782126622830","authorId":3579782126622830,"name":"Sephy","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":157068326,"type":1,"supId":5136865,"prevId":0,"content":"its correlated to bitcoin and ethereum prices","text":"its correlated to bitcoin and ethereum prices","html":"its correlated to bitcoin and ethereum prices"},{"id":5138717,"gmtCreate":1625578658767,"gmtModify":1635235877992,"authorId":3579782126622830,"author":{"id":3579782126622830,"idStr":"3579782126622830","authorId":3579782126622830,"name":"Sephy","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3579782126622830,"repliedAuthor":{"id":3579782126622830,"idStr":"3579782126622830","authorId":3579782126622830,"name":"Sephy","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":157068326,"type":1,"supId":5136859,"prevId":5138681,"content":"The previous ER their price went up to 300, the upcoming ER i am confident it will go to 32x at least depending on btc n eth price","text":"The previous ER their price went up to 300, the upcoming ER i am confident it will go to 32x at least depending on btc n eth price","html":"The previous ER their price went up to 300, the upcoming ER i am confident it will go to 32x at least depending on btc n eth price"},{"id":5138775,"gmtCreate":1625578847799,"gmtModify":1635235874673,"authorId":3579782126622830,"author":{"id":3579782126622830,"idStr":"3579782126622830","authorId":3579782126622830,"name":"Sephy","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":157068326,"type":1,"supId":5136859,"prevId":0,"content":"Btw im not a bagholder im a professional trader, good luck @@","text":"Btw im not a bagholder im a professional trader, good luck @@","html":"Btw im not a bagholder im a professional trader, good luck @@"}],"langContent":"EN"},{"id":157018461,"gmtCreate":1625552980053,"gmtModify":1631890737445,"author":{"id":"4088222297029790","authorId":"4088222297029790","name":"StanleyO","avatar":"https://static.tigerbbs.com/95419e33f00da5cc2a2d8341c1c80638","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4088222297029790","authorIdStr":"4088222297029790"},"htmlText":"Good Read","listText":"Good Read","text":"Good Read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/157018461","repostId":1164348327,"repostType":4,"repost":{"id":"1164348327","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"<p>For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmark<b>S&amp;P 500</b>has gained more than 90% since hitting its bear-market bottom on March 23, 2020.</p>\n<p>While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.</p>\n<p>Coinbase Global</p>\n<p>First up is cryptocurrency exchange and ecosystem<b>Coinbase Global</b>(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes of<b>Bitcoin</b>&nbsp;and<b>Ethereum</b>. The problem is there are a trio of catalysts working against the Coinbase brokerage model.</p>\n<p>To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.</p>\n<p>Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.</p>\n<p>And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.</p>\n<p>Cassava Sciences</p>\n<p>Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stock<b>Cassava Sciences</b>(NASDAQ:SAVA).</p>\n<p>Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.</p>\n<p>I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception of<b>Biogen</b>'s Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.</p>\n<p>Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.</p>\n<p>GameStop</p>\n<p>If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailer<b>GameStop</b>(NYSE:GME).</p>\n<p>On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.</p>\n<p>However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.</p>\n<p>GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.</p>\n<p>Inovio Pharmaceuticals</p>\n<p>Biotech stocks can offer ample opportunity, or in<b>Inovio Pharmaceuticals</b>'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.</p>\n<p>Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.</p>\n<p>For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.</p>\n<p>If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.</p>\n<p>AMC Entertainment</p>\n<p>Finally, I can't forgetongoing pump-and-dump scheme<b>AMC Entertainment</b>(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.</p>\n<p>AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.</p>\n<p>AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.</p>\n<p>I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 09:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/><strong>The motley fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","AMC":"AMC院线","GME":"游戏驿站","COIN":"Coinbase Global, Inc.","INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":157001438,"gmtCreate":1625550244324,"gmtModify":1633939729034,"author":{"id":"3566293775093626","authorId":"3566293775093626","name":"Patek1975","avatar":"https://static.tigerbbs.com/a2e5f9a5d563704aaf5f2473be16f148","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3566293775093626","authorIdStr":"3566293775093626"},"htmlText":"Lousy article as usual from fools , how much yougetting paid for this article&nbsp;","listText":"Lousy article as usual from fools , how much yougetting paid for this article&nbsp;","text":"Lousy article as usual from fools , how much yougetting paid for this article","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/157001438","repostId":1164348327,"repostType":2,"repost":{"id":"1164348327","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"<p>For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmark<b>S&amp;P 500</b>has gained more than 90% since hitting its bear-market bottom on March 23, 2020.</p>\n<p>While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.</p>\n<p>Coinbase Global</p>\n<p>First up is cryptocurrency exchange and ecosystem<b>Coinbase Global</b>(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes of<b>Bitcoin</b>&nbsp;and<b>Ethereum</b>. The problem is there are a trio of catalysts working against the Coinbase brokerage model.</p>\n<p>To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.</p>\n<p>Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.</p>\n<p>And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.</p>\n<p>Cassava Sciences</p>\n<p>Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stock<b>Cassava Sciences</b>(NASDAQ:SAVA).</p>\n<p>Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.</p>\n<p>I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception of<b>Biogen</b>'s Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.</p>\n<p>Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.</p>\n<p>GameStop</p>\n<p>If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailer<b>GameStop</b>(NYSE:GME).</p>\n<p>On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.</p>\n<p>However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.</p>\n<p>GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.</p>\n<p>Inovio Pharmaceuticals</p>\n<p>Biotech stocks can offer ample opportunity, or in<b>Inovio Pharmaceuticals</b>'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.</p>\n<p>Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.</p>\n<p>For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.</p>\n<p>If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.</p>\n<p>AMC Entertainment</p>\n<p>Finally, I can't forgetongoing pump-and-dump scheme<b>AMC Entertainment</b>(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.</p>\n<p>AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.</p>\n<p>AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.</p>\n<p>I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 09:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/><strong>The motley fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","AMC":"AMC院线","GME":"游戏驿站","COIN":"Coinbase Global, Inc.","INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":157001313,"gmtCreate":1625550203332,"gmtModify":1633939729514,"author":{"id":"3566293775093626","authorId":"3566293775093626","name":"Patek1975","avatar":"https://static.tigerbbs.com/a2e5f9a5d563704aaf5f2473be16f148","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3566293775093626","authorIdStr":"3566293775093626"},"htmlText":"Apes hold [Smile]&nbsp;","listText":"Apes hold [Smile]&nbsp;","text":"Apes hold [Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/157001313","repostId":1164348327,"repostType":2,"repost":{"id":"1164348327","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"<p>For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmark<b>S&amp;P 500</b>has gained more than 90% since hitting its bear-market bottom on March 23, 2020.</p>\n<p>While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.</p>\n<p>Coinbase Global</p>\n<p>First up is cryptocurrency exchange and ecosystem<b>Coinbase Global</b>(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes of<b>Bitcoin</b>&nbsp;and<b>Ethereum</b>. The problem is there are a trio of catalysts working against the Coinbase brokerage model.</p>\n<p>To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.</p>\n<p>Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.</p>\n<p>And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.</p>\n<p>Cassava Sciences</p>\n<p>Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stock<b>Cassava Sciences</b>(NASDAQ:SAVA).</p>\n<p>Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.</p>\n<p>I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception of<b>Biogen</b>'s Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.</p>\n<p>Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.</p>\n<p>GameStop</p>\n<p>If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailer<b>GameStop</b>(NYSE:GME).</p>\n<p>On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.</p>\n<p>However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.</p>\n<p>GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.</p>\n<p>Inovio Pharmaceuticals</p>\n<p>Biotech stocks can offer ample opportunity, or in<b>Inovio Pharmaceuticals</b>'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.</p>\n<p>Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.</p>\n<p>For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.</p>\n<p>If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.</p>\n<p>AMC Entertainment</p>\n<p>Finally, I can't forgetongoing pump-and-dump scheme<b>AMC Entertainment</b>(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.</p>\n<p>AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.</p>\n<p>AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.</p>\n<p>I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 09:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/><strong>The motley fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","AMC":"AMC院线","GME":"游戏驿站","COIN":"Coinbase Global, Inc.","INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":154754276,"gmtCreate":1625548066895,"gmtModify":1633939746786,"author":{"id":"3583491361400942","authorId":"3583491361400942","name":"Xuehao","avatar":"https://static.tigerbbs.com/68f8f0968bdff0787e4a34cf6caf8f84","vip":1,"crmLevel":8,"crmLevelSwitch":0,"idStr":"3583491361400942","authorIdStr":"3583491361400942"},"htmlText":"Too the moonn,&nbsp; like n share tq","listText":"Too the moonn,&nbsp; like n share tq","text":"Too the moonn, like n share tq","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/154754276","repostId":1164348327,"repostType":4,"repost":{"id":"1164348327","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"<p>For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmark<b>S&amp;P 500</b>has gained more than 90% since hitting its bear-market bottom on March 23, 2020.</p>\n<p>While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.</p>\n<p>Coinbase Global</p>\n<p>First up is cryptocurrency exchange and ecosystem<b>Coinbase Global</b>(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes of<b>Bitcoin</b>&nbsp;and<b>Ethereum</b>. The problem is there are a trio of catalysts working against the Coinbase brokerage model.</p>\n<p>To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.</p>\n<p>Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.</p>\n<p>And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.</p>\n<p>Cassava Sciences</p>\n<p>Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stock<b>Cassava Sciences</b>(NASDAQ:SAVA).</p>\n<p>Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.</p>\n<p>I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception of<b>Biogen</b>'s Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.</p>\n<p>Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.</p>\n<p>GameStop</p>\n<p>If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailer<b>GameStop</b>(NYSE:GME).</p>\n<p>On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.</p>\n<p>However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.</p>\n<p>GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.</p>\n<p>Inovio Pharmaceuticals</p>\n<p>Biotech stocks can offer ample opportunity, or in<b>Inovio Pharmaceuticals</b>'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.</p>\n<p>Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.</p>\n<p>For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.</p>\n<p>If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.</p>\n<p>AMC Entertainment</p>\n<p>Finally, I can't forgetongoing pump-and-dump scheme<b>AMC Entertainment</b>(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.</p>\n<p>AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.</p>\n<p>AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.</p>\n<p>I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 09:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/><strong>The motley fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","AMC":"AMC院线","GME":"游戏驿站","COIN":"Coinbase Global, Inc.","INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":181,"commentSize":33,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1164348327"}